

Working title: Health-related quality of life of female sex workers living with HIV in South Africa: a cross-sectional study

Authors: Linwei Wang¹, David W. Dowdy², Carly A. Comins², Katherine Young³, Mfezi Mcingana³, Ntambue Mulumba³, Hlengiwe Mhlophe³, Claire Chen², Harry Hausler³, Sheree R. Schwartz², Stefan Baral², Sharmistha Mishra^{§1,4,5,6}, on behalf of the Siyaphambili Study team

Affiliations: ¹MAP-Centre for Urban Health Solutions, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada; ²Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA; ³TB HIV Care, South Africa; ⁴Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada; ⁵Department of Medicine, Division of Infectious Disease, University of Toronto, Toronto, ON, Canada; ⁶Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada.

§ Corresponding Author:

Sharmistha Mishra, MD, MSc, PhD
MAP-Centre for Urban Health Solutions
St. Michael's Hospital, Unity Health Toronto
University of Toronto
209 Victoria St, Toronto, ON M5B 1T8
E: sharmistha.mishra@utoronto.ca
T: 416-864-5746

E-mail addresses of authors:

LW: Linwei.Wang@unityhealth.to
DWD: ddowdy1@jhmi.edu
CAC: ccomins1@jhu.edu
KY: katherine@tbhivcare.org
MM: Mfezi@tbhivcare.org
NM: Ntambue@tbhivcare.org
HM: Hlengiwe@tbhivcare.org
CC: cchen252@jhu.edu
HH: Hhausler@tbhivcare.org
SRS: sschwartz@jhu.edu
SB: sbaral@jhu.edu
SM: sharmistha.mishra@utoronto.ca

Key words: female sex worker; HIV; health-related quality of life; health utility; drug use; violence; stigma

Abstract: 350/350

Word Count: 3493/3500

1 **ABSTRACT [350/350]**
2

3 **Introduction:** Health-related quality of life (HRQoL) is an important HIV outcome beyond viral
4 suppression. However, there are limited data characterizing HRQoL of key populations including
5 female sex workers (FSW) living with HIV.
6

7 **Methods:** We used baseline data (June 22, 2018-March 23, 2020) of FSW who were diagnosed
8 with HIV and enrolled into a randomized trial in Durban, South Africa. HRQoL information was
9 collected by a generic preference-accompanied tool with five domains (EQ-5D), and
10 summarized into a single score (range 0-1) which represents health utility. We employed
11 multivariable beta regression models to identify determinants of HRQoL and to estimate
12 subgroup-specific HRQoL score. Using external estimates of life expectancy and population
13 size, we estimated the number of quality adjusted life years reduced among FSW living with HIV
14 in South Africa associated with violence and drug use.
15

16 **Results:** Of 1363 individuals (mean age: 32.4 years; mean HRQoL score: 0.857) in our
17 analysis, 62.6% used drugs, 61.3% experienced physical or sexual violence, and 64.6% self-
18 reported taking antiretroviral treatment (ART). The following were associated with a reduction in
19 the average marginal HRQoL score: older age (per decade: 0.018 [95% confidence interval (CI):
20 0.008, 0.027]), drug use (0.022 [0.007, 0.036]), experience of violence (0.024 [0.010, 0.038]),
21 and moderate (vs. no) level of internalized stigma (0.023 [0.004, 0.041]). Current ART use was
22 associated with a 0.015-point (-0.001, 0.031) increase in the HRQoL score. The estimated
23 mean (95%CI) HRQoL scores ranged from 0.838 (0.816, 0.860) for FSW who used drugs,
24 experienced violence, and were not on ART; to 0.899 (0.883, 0.916) for FSW who did not use
25 drugs nor experience violence and were on ART. Our results can be translated into a reduction
26 in 37,184 and 39,722 quality adjusted life years related to drug use and experience of violence,
27 respectively in South Africa.
28

29 **Conclusions:** These results demonstrate the association of ART with higher HRQoL among
30 FSW and the need to further address structural risks including drug use, violence, and stigma.
31 Population-specific estimates of HRQoL score can be further used to calculate quality-adjusted
32 life years in economic evaluations of individual and structural interventions addressing the
33 needs of FSW living with HIV.
34

35 **Clinical Trial Registration:** NCT03500172 (April 17, 2018)
36
37

38 INTRODUCTION

39

40 Globally, there has been remarkable progress towards the UNAIDS 90-90-90 HIV testing and
41 treatment targets. By the end of 2019, 81% of people living with HIV (PLHIV) knew their status,
42 of whom 83% were on antiretroviral treatment (ART), and 88% of those on ART were virally
43 suppressed(1). Although much work remains to improve the cascade of HIV care in order to
44 achieve the new 95-95-95 targets by 2030(2), there is growing recognition of the importance of
45 patient-centered chronic care to improve patient-reported outcomes such as health-related
46 quality of life (HRQoL)(3, 4). Some have proposed that good HRQoL should be explicitly
47 included as the 'fourth' target as part of the HIV care cascade(4).

48

49 HRQoL is a multidimensional concept defined as a person's subjective perception of the impact
50 of ill health on daily life and includes physical, psychological and social functioning(5). Most
51 existing studies on HRQoL among PLHIV have identified CD4 count, gender, age, and ART use
52 as common determinants for HRQoL(6-9). The majority of these studies have been conducted
53 in wider populations of PLHIV in high income settings(8), though some have been performed in
54 low and middle income settings including sub-Saharan Africa(7, 8). There is a dearth of
55 research regarding HRQoL in key populations living with HIV in high prevalence settings,
56 including among female sex workers (FSW).

57

58 In South Africa, FSW have a high burden of HIV(10). Approximately 90,000 FSW in South Africa
59 are living with HIV, representing nearly 60% of all women engaged in sex work(10). FSW living
60 with HIV face a wide range of challenges, including HIV progression, comorbidities, drug use,
61 stigma, and other social and structural vulnerabilities(3, 8, 9) resulting in suboptimal treatment
62 uptake and viral suppression(11-13). Data, although limited, suggest that less than 40% of FSW
63 living with HIV are virally suppressed(11). However, it is unclear how these challenges have
64 shaped FSW's self-perception of their well-being. A meta-analysis across 31 studies in low and
65 middle income settings found highly prevalent mental health conditions among FSW, including
66 depression, anxiety, post-traumatic stress disorder, and suicidal thoughts and attempts(14).
67 However, these studies examined FSW in general, instead of PLHIV, and with a focus on
68 mental health rather than HRQoL(14).

69

70 HRQoL as a multidimensional concept can also be summarized into a single metric of health
71 utility, which is important for economic evaluations of HIV interventions(6, 7, 15). For example,
72 preference-accompanied measures of HRQoL such as the EQ-5D (captures self-rated
73 information in five domains - mobility, self-care, ability to do usual activities, pain/discomfort, and
74 anxiety/depression, accompanied by a set of health state utility values) are often summarized
75 into a single score representing health utility, and used to calculate quality-adjusted life years
76 (QALYs) to be applied in cost-utility analyses(15-19). A review of the economic evaluation
77 literature on HIV interventions in sub-Saharan Africa reveals that the weights assigned to
78 QALYs often have an insufficient evidence due to lack of data on setting- and population-
79 specific measures(7, 20).

80

81 To address these gaps, we aimed to examine HRQoL across the five EQ-5D domains, estimate
82 HRQoL scores which represent health utilities, and identify characteristics associated with
83 HRQoL scores among FSW living with HIV in Durban, South Africa.

84

85 **METHODS**

86

87 *Study design and subjects*

88

89 The current analysis uses baseline data from an adaptive randomized intervention trial
90 (Siyaphambili study) involving FSW in Durban, South Africa(11). Cisgender women who were
91 18 years and older, selling sex as their main source of income, residing in Durban, and
92 diagnosed with HIV at least 6 months prior to study enrollment were eligible. Full details of the
93 study have been described elsewhere(11) and in **Appendix 0**.

94

95 Following informed consent and enrollment, participants provided whole blood samples which
96 were used to assess baseline CD4 count and viral load by the South African National Health
97 Laboratory Services per national guidelines. Individuals completed an interviewer-administered
98 questionnaire that elicited information including socio-demographics, personal/sexual history,
99 HIV care, drug use, and HRQoL.

100

101 All FSW recruited between June 22, 2018 and March 23, 2020 who completed their baseline
102 questionnaire were included. Individuals were excluded if their responses to the primary
103 outcome (described below) were missing.

104

105 *Measures*

106

107 HRQoL information was collected using the generic preference-accompanied measure - EQ-5D-
108 3L(16). EQ-5D-3L measures HRQoL in five domains (mobility, self-care, ability to do usual
109 activities, pain/discomfort, and anxiety/depression), and each domain is measured with three
110 levels (1=no problems, 2=some/moderate problems, and 3=extreme problems). The answers
111 can be assembled into a 5-digit health state reflecting the score on each dimension, resulting in
112 a total of 243 plausible health states (3^5). EQ-5D also contains a separate question which asks
113 participants to directly rate their health state from the best (score of 100) to the worst (score of
114 0) (referred to as EQ visual analogue scale (EQ-VAS)). EQ-5D has been used to measure
115 HRQoL of the wider population and PLHIV across settings including South Africa(7, 8, 21, 22).
116 EQ-5D is also a guideline-recommended instrument to derive health utility measures(15, 23).

117

118 Our primary outcome was a summary HRQoL score, representing health utility. The HRQoL
119 score was calculated using the 5-digit health states combined with valuations of the health
120 states from the wider population (value set). A wider population value set is used to reflect the
121 preferences of local taxpayers and potential receivers of healthcare(16). We used the value set
122 obtained from the population in Zimbabwe(21). The calculated HRQoL score ranges between 0-
123 1, where 0 represents a state equivalent to death and 1 represents perfect health.

124

125 Our secondary outcomes included EQ-VAS, each of the EQ-5D-3L domains, and a binary
126 variable indicating no reported problem on all five EQ-5D-3L domains (perfect health).

127
128 We defined an a priori set of covariates based on evidence from the literature regarding their
129 associations with HRQoL(7, 9, 24). These covariates included sociodemographics, clinical
130 features and treatment of HIV, drug use and other social and structural factors. Specifically, we
131 considered age, race, education, ART experience, CD4 count, viral load, drug use in the past 30
132 days, lifetime injection drug use, experience of homelessness in the past 6 months, lifetime
133 experience of physical or sexual violence, experience with stigma related to HIV or sex work,
134 and internalized stigma related to sex work. Details of each variable are shown in **Table 1** and
135 **Appendix A1**.

136
137 *Statistical analysis*

138
139 First, we examined the descriptive characteristics of the study sample at baseline; assessed the
140 distribution of our primary and secondary measures of HRQoL; and compared the differences in
141 the HRQoL score, and of EQ-VAS, by covariates. Wilcoxon rank-sum and Kruskal-Wallis tests
142 were used to compare the median values in outcomes across binary variables and other
143 categorical variables, respectively.

144
145 Second, we employed multivariable beta regression models with a complementary log-log link
146 and fixed dispersion to investigate associations between covariates of interest and the HRQoL
147 score(25). Beta regression models provide a flexible approach to modeling health utility values
148 which are truncated and skewed(25). We provide details on model selection in **Appendix A2**.
149 We present the results as average marginal effects along with 95% confidence intervals (CIs),
150 which reflect the magnitude of association between a one-unit change in covariates and the
151 mean HRQoL score(26).

152
153 Using the fitted model, we estimated the mean and 95% CIs of HRQoL score for subgroups of
154 FSW defined by identified determinants of HRQoL score, setting the rest covariates at the
155 sample average values. In addition, assuming an average remaining life expectancy of 30
156 years(27), and an estimated 90,000 FSW living with HIV in South Africa(10), using the observed
157 prevalence of drug use and experience of violence, we estimated the number of QALYs related
158 to drug use and experience of violence, respectively in South Africa.

159
160 Third, we performed a set of multivariable regression analyses to examine the relationship
161 between the covariates of interest and our secondary outcomes. Multivariable linear regression
162 was used to model EQ-VAS. Multivariable logistic regression was used to model each of the
163 EQ-5D-3L domains, and the perfect health state, separately. We grouped each EQ-5D-3L
164 domain into two levels (reporting moderate/extreme vs. no problems).

165
166 Lastly, to examine the sensitivity of our results to the value set used, we computed a new
167 HRQoL score using the value set obtain from the wider population in UK(22). We repeated the

168 multivariable beta regression analysis to examine the relationship between covariates of interest
169 and the new HRQoL score.

170
171 All statistical analyses were executed in R version 3.6.2. R package 'eq5d' was used to
172 calculate the HRQoL score(28), 'betareg' was used for beta regression analysis(25), and
173 'margins' was used to estimate average marginal effects(26).

174 175 **RESULTS**

176
177 Of 1363 individuals included in our analysis, the majority (97.4%) self-identified as black, and
178 the mean age was 32.4 years (standard deviation: 8.0; median: 31.0; interquartile range: 26.6-
179 36.7). We excluded 28 (2.0%) individuals because they were missing the primary outcome
180 (**Appendix Figure A3.1** shows the details on exclusion). Overall, 853 individuals (62.6%)
181 reported using drugs in the past 30 days, 397 (29.1%) experienced homelessness in the past
182 six months, 835 (61.3%) ever experienced physical or sexual violence, and 1199 (88.0%)
183 reported either experience with stigma (n=957, 70.2%) or internalized stigma (n=819, 60.1%).
184 All individuals were diagnosed with HIV prior to study entry, of whom 178 (13.1%) self-reported
185 being ART naïve while 880 (64.6%) reported being on ART, and 303 (22.2%) reported prior, but
186 non-current ART use at time of enrollment. According to blood tests conducted at study entry,
187 510 (37.4%) individuals were virally suppressed (<50 copies/ml). **Table 1** provides details on
188 sample characteristics.

189
190 Regarding the five domains of EQ-5D, the majority of individuals reported no problems in
191 mobility (95.7%), self-care (99.0%), and usual activity (96.9%); while 32.9% and 40.7% reported
192 at least some problems in pain/discomfort, and in anxiety/depression, respectively (**Figure 1A**).
193 Of the 243 plausible health states summarized across EQ-5D domains, we observed 47; the 12
194 most frequent health states represented more than 95% of all observations (**Figure 1B**).
195 Individuals with a perfect health state accounted for more than half (52.5%) of the sample
196 (**Figure 1B**). The HRQoL score was heavily left-skewed, ranging from 0.233 to 1, with a median
197 of 1 [interquartile range: 0.787,1] and mean of 0.857 (standard deviation: 0.187) (**Figure 1C**).
198 EQ-VAS ranged from 0 to 100, with a median of 52.0 [50.0, 70.0] and mean of 57.7 (21.9)
199 (**Figure 1D**).

200
201 **Table 2** presents the summary statistics of HRQoL score and EQ-VAS by sample characteristic.
202 The median HRQoL score was higher in younger individuals (1.00 vs. 0.854, comparing ages
203 18-34 vs. 35-64, p=0.006); those identified as black (1.00 vs. 0.854, p=0.008) and reported
204 current ART use (1.00 vs. 0.854, p=0.001). In contrast, the median HRQoL score was lower in
205 individuals who used drugs (0.854 vs. 1.00, p<0.001), and who experienced homelessness
206 (0.854 vs. 1.00, p=0.014) or violence (0.854 vs. 1.00, p<0.001). We did not observe a difference
207 in HRQoL score by CD4 count nor by viral load. However, individuals with higher CD4 counts
208 and lower viral load had higher EQ-VAS (p<0.001, **Table 2**); and those with experience of or
209 internalized stigma had lower EQ-VAS (p<0.001, **Table 2**).

210

211 In the multivariable regression analyses, we excluded another 87 (6.4%) individuals because
212 they had missing covariate information (**Appendix Figure A3.1**). Individuals excluded were
213 younger, less likely to be on ART, and more likely to experience homelessness compared to
214 those included (**Appendix Table A3.1**). We found that age (per ten-year increase), drug use,
215 and violence experience were associated with 0.018 (95% CI: 0.008, 0.027), 0.022 (0.007,
216 0.036), and 0.024 (0.010, 0.038) lower average marginal HRQoL score, respectively (**Table 3**).
217 Current ART use was associated with 0.015 (-0.001, 0.031) higher average marginal HRQoL
218 score (**Table 3**). We did not find a difference in HRQoL score between individuals who were
219 ART naïve and who had previously been but were not currently on ART (results not shown; we
220 thus combined these two groups in models). Individuals with moderate internalized stigma had
221 0.023 (0.004, 0.041) lower average marginal HRQoL score compared to those without;
222 however, we did not observe a difference between those with extreme versus no internalized
223 stigma (**Table 3**). We did not find independent associations between education, CD4 count, viral
224 load, homelessness, or stigma experience with HRQoL score (**Table 3**).

225
226 Based on the fitted model, the estimated mean (95% CI) HRQoL scores were 0.870 (0.854,
227 0.886) for FSW living with HIV overall, 0.877 (0.862, 0.893) and 0.862 (0.843, 0.882) for those
228 with and without current ART use, respectively. **Figure 2** shows estimates of HRQoL score for
229 other subgroups of FSW. For example, the model estimated mean HRQoL scores of 0.838
230 (0.816, 0.860) for FSW who used drugs, experienced violence, and were not on ART, versus
231 0.899 (0.883, 0.916) for FSW who did not use drugs nor experience violence and were on ART.
232 Our results can be translated into a reduction in 37,184 and 39,722 QALYs related to drug use
233 and violence experience, respectively in South Africa.

234
235 Multivariable analyses of secondary HRQoL outcomes identified some similarities and
236 differences in terms of variables associated HRQoL (**Table 3; Appendix Figure A3.2**). For
237 example, age and drug use were not independently associated with EQ-VAS (**Table 3**).
238 Homelessness was associated with lower EQ-VAS (-0.027 (-0.053, -0.001)) (**Table 3**). We
239 observed a dose-response relationship between both stigma variables and EQ-VAS, where
240 increasing stigma was associated with lower EQ-VAS (**Table 3**). When we analyzed the five
241 domains of EQ-5D separately, we found homelessness was associated with increased odds of
242 reporting any problem in mobility (1.72 (0.95, 3.09)), and in pain/discomfort (1.46 (1.11, 1.90))
243 ((**Appendix Figure A3.2**).

244
245 Our sensitivity analysis using a UK-based value set revealed similar results (**Appendix Table**
246 **A3.2**).

247 248 **DISCUSSION**

249
250 There has been limited study of HRQoL among FSW living with HIV across Sub-Saharan Africa
251 including the estimation of health utility. Among 1363 FSW who were diagnosed with HIV and
252 enrolled into an adaptive randomized trial via HIV prevention and treatment program for sex
253 workers in Durban, we found older age, lack of ART use, drug use, experience of violence, and
254 moderate (vs. no) level of internalized stigma were associated with lower HRQoL score at the

255 time of enrollment. In addition, we present the overall, and subgroup-specific estimates of
256 HRQoL scores, which can be used to calculate QALYs in cost-utility analysis of interventions
257 focused on FSW living with HIV in South Africa.

258
259 The observed average HRQoL score for FSW living with HIV was 0.857 (model estimated mean
260 of 0.870 (95% CI: 0.854, 0.886)), which is somewhat lower than an estimate from the wider
261 population living with HIV in South Africa between 2013-2015 (0.89(24)), when evaluated using
262 the same value set(21). In fact, the lower HRQoL score for FSW living with HIV stemmed largely
263 from concerns in pain/discomfort (32.9% of FSW in our study reported pain/discomfort vs. 5% of
264 wider population living with HIV in South Africa(24)) and anxiety/depression (40.7% vs. 5%(24)).
265 Our findings are consistent with previous studies which found higher burden of mental health
266 conditions among FSW in low and middle income settings compared to the wider population,
267 though none of these studies directly estimated HRQoL as a measure of health utility(14). The
268 associations between lower HRQoL and drug use, as well as experience of violence, were also
269 consistent with this recent meta-analysis(14). Lower HRQoL associated with experience of
270 violence may reflect pain and psychologic effects (e.g., depression, or post-trauma syndrome)
271 of violence (29). Lower HRQoL associated with drug use may reflect self-medication as a
272 coping strategy in the context of chronic pain or depression(30, 31), and/or reflect mental health
273 effects of chronic use of drugs(31). The high prevalence of drug use (62.6%), and experience of
274 violence (61.3%) among FSW living with HIV, and their associations with lower HRQoL further
275 demonstrate the synergistic epidemics of substance abuse, violence and HIV/AIDS (SAVA
276 syndemic) among women(29, 32); and highlight the need for integrated services to prevent and
277 mitigate the effects of violence and drug use to help improve the well-being among sex workers.
278

279 We also observed a high prevalence of homelessness (29%) and experience of stigma or
280 internalized stigma (88%) among FSW living with HIV in the study. Although we did not observe
281 an independent association between experience of homelessness or stigma with HRQoL score,
282 homelessness was associated with increased odds of reporting problems in mobility,
283 pain/discomfort, as well as lower EQ-VAS. We also found a strong negative dose-response
284 relationship between levels of stigma and the EQ-VAS. These findings suggest a strong
285 negative subjective experience of stigma, even if this experience is not reflected in self-reported
286 problems on the EQ-5D domains. Although generic preference-accompanied measures of
287 HRQoL such as EQ-5D allow for calculation of HRQoL scores which enables comparison
288 across groups with different diseases, these measures do not capture other aspects of HRQoL
289 such as social relationships, spirituality, and environment (e.g., physical safety and
290 security)(33), and may be insensitive to specific issues faced by specific populations(34).
291 Moreover, HRQoL score is calculated by valuing individual's self-rated health state from a wider
292 population's perspective of health preference, which contrasts with EQ-VAS, reflecting purely
293 individual's subjective perception of health(16). Other reasons underlying the non-monotonic
294 relationship (although not statistically significant) between stigma and self-reported problems on
295 the EQ-5D domains may include the following: stigma may be associated with individual's
296 definition/perception of 'having a problem'/tolerance levels of the problem(35); as well as
297 individual's tendency to provide socially desirable answers(36). Future studies using disease-
298 specific HRQoL measures such as the WHOQOL-HIV BREF (33) and exploring various

299 underlying types of stigma(37) may provide additional insights into the relationship between
300 stigma and HRQoL among FSW living with HIV. Our findings of high prevalence of stigma and
301 its association with poorer self-perceived overall HRQoL further highlight the need to evaluate
302 interventions to combat intersectional stigma (e.g., the convergence of multiple stigmatized
303 attributes) for key populations(38).

304
305 Despite heterogeneity in HRQoL across subgroups of FSW living with HIV, we found that
306 current ART use was independently associated with higher HRQoL. These results are
307 consistent with previous studies among the wider population(7, 15, 24), including studies with
308 longitudinal design which found improvement in HRQoL following ART initiation(39). For
309 example, among a random sample of the wider adult population in South Africa, Thomas et al.,
310 showed that there was no difference in HRQoL among individuals on ART compared to HIV-
311 negative individuals(24). Collectively, these findings demonstrate the association between ART
312 and higher HRQoL among PLHIV, and the importance of improving ART retention.

313
314 We did not observe an independent association between CD4 count or viral load with HRQoL in
315 our study. Although HRQoL scores (utility measures) for PLHIV are often stratified by CD4
316 count (with lower CD4 counts correlated with lower weights), these estimates were obtained
317 before ART became widely available(6). Indeed, in the United States, more recent utility
318 estimates have been found to be more similar across CD4 count strata and to have a narrower
319 range than pre-ART measures(6). Studies have shown that virally suppressed individuals still
320 experience high levels of symptom-related distress, such as fatigue and energy loss, insomnia,
321 sadness and depression, sexual dysfunction and changes in body appearance(40), which likely
322 reduce their HRQoL. These results support that viral suppression is an essential but not sole
323 end point of HIV care, and there is a need to improve HIV outcomes beyond viral suppression(3,
324 4).

325
326 Our study has several limitations. Our sample did not include FSW living with HIV who were
327 either undiagnosed or diagnosed recently. However, a previous study in South Africa has shown
328 similar HRQoL score between those undiagnosed and those on ART(24). As such, one might
329 be able to approximate the HRQoL score for FSW living with undiagnosed HIV using our
330 estimates of FSW on ART. Our results could be subject to selection bias to the extent that
331 women reached by the sex worker programs and who consented to enroll into the study were
332 different from their counterparts. Nevertheless, it is essential to study HRQoL in marginalized
333 populations such as FSW in high-burden countries. We relied on individuals' self-report of ART
334 use which might be affected by recall bias. In addition, we used the EQ-5D health state
335 valuations from Zimbabwe, as valuations for South Africa were not available. Our sensitivity
336 analyses using UK valuations produced similar results. Moreover, Zimbabwe value set was
337 obtained in 2000(21). Individual preferences for health states might have changed over time.
338 However, the same value set was commonly used to calculate HRQoL scores across
339 populations in South Africa(24), facilitating the comparison of our estimates against others. Our
340 analyses were based on cross-sectional data and thus cannot be used to infer causality.
341 Caution should be exercised when applying our estimates to FSW populations in different
342 settings.

343
344
345
346
347
348
349
350
351
352
353
354
355

CONCLUSIONS

In summary, we evaluated the overall and characteristics associated with HRQoL for FSW living with HIV in South Africa and presented both overall and subgroup-specific estimates of HRQoL score, representing health utility. The findings here reinforce the importance for HIV and sex worker programs to develop and adopt a comprehensive, and human-centered approach, with tailored services designed to address social and structural vulnerabilities including drug use, violence, and stigma to improve HRQoL among FSW living with HIV. In addition, monitoring of HRQoL could provide an actionable measure during program evaluation, and thus inform service adaptation or scale-up to improve the overall well-being among FSW living with HIV.

356 **Declarations**

357

358 *Ethics approval and consent to participate*

359

360 The study was approved by the University of the Western Cape Biomedical Research Ethics
361 Committee in South Africa; the Johns Hopkins School of Public Health Institutional Review
362 Board in the United States, and the eThekweni Municipality and KwaZulu-Natal Provincial
363 Departments of Health. Participants provided informed consent prior to enrollment.

364

365 *Consent for publication*

366

367 Not applicable.

368

369 *Availability of data and materials*

370

371 The data that support the findings of this study are available from the author, [SB], upon
372 reasonable request and approval.”

373

374 *Competing interests*

375

376 There are no conflicts of interest to disclose.

377

378 *Funding*

379

380 This study was funded by the National Institutes of Health (R01NR016650).

381

382 *Author's contribution*

383

384 All listed authors contributed significantly to the work. LW and SM conceptualized and designed
385 the study. CAC, KY, MM, NM, and HM contributed to the data collection. LW and CAC cleaned
386 the data. CC provided critical inputs into data cleaning. LW conducted the data analyses,
387 interpreted the results, and drafted the manuscript. DWD and SM provided critical inputs into the
388 analyses. DWD, CAC, KY, MM, NM, HM, CC, HH, SRS, SB, and SS contributed to the
389 interpretation of results and provided critical manuscript revision. KY, MM, NM, HM, and HH
390 provided important inputs from a local programming perspectives.

391

392

393 **List of Abbreviations:**

394

395 HRQoL: health-related quality of life

396 PLHIV: people living with HIV

397 FSW: female sex workers (FSW)

398 ART: antiretroviral treatment

399 QALY: quality adjusted life years

400 CI: confidence interval

401 VAS: visual analogue scale

402 EQ-5D-3L: EuroQoL five dimension, three level

403

404 **Additional files**

405

406 Title of the additional file 1: Health-related quality of life among female sex workers living with
407 HIV in South Africa Appendix.

408

409 Format: word doc.

410

411 Contents: This additional file includes the following sections and have been cited accordingly in
412 the main text: A1. Details on stigma measures; A2. Details on model fitting and comparison; A3.
413 Supplementary results.

414

415

416

417 REFERENCES

418

- 419 1. UNAIDS. Global AIDS Update 2020. Seizing the moment: Tackling entrenched inequalities to end
420 epidemics Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2020.
- 421 2. HIV/AIDS JUNPo. Understanding fast-track: Accelerating action to end the AIDS epidemic by
422 2030. Switzerland; 2015.
- 423 3. The Lancet H. Living well with HIV. *Lancet HIV*. 2019;6(12):e807.
- 424 4. Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo Valero J, et al.
425 Beyond viral suppression of HIV - the new quality of life frontier. *BMC Med*. 2016;14(1):94.
- 426 5. Ferrans CE. Definitions and conceptual models of quality of life. . In: Lipscomb J GC, Snyder C, ,
427 editor. *Outcomes assessment in cancer*. Cambridge, England: Cambridge University; 2005. p. 14-30.
- 428 6. Whitham HK, Hutchinson AB, Shrestha RK, Kuppermann M, Grund B, Shouse RL, et al. Health
429 Utility Estimates and Their Application to HIV Prevention in the United States: Implications for Cost-
430 Effectiveness Modeling and Future Research Needs. *MDM Policy Pract*. 2020;5(2):2381468320936219.
- 431 7. Robberstad B, Olsen JA. The health related quality of life of people living with HIV/AIDS in sub-
432 Saharan Africa - a literature review and focus group study. *Cost Eff Resour Alloc*. 2010;8:5.
- 433 8. Cooper V CJ, Harding R, Whetham J,. Measuring quality of life among people living with HIV: a
434 systematic review of reviews. *Health and quality of life outcomes*. 2017;15(1):1-20.
- 435 9. Drewes J, Gusy B, Ruden U. More than 20 years of research into the quality of life of people with
436 HIV and AIDS--a descriptive review of study characteristics and methodological approaches of published
437 empirical studies. *J Int Assoc Provid AIDS Care*. 2013;12(1):18-22.
- 438 10. Baral S, Beyrer C, Muessig K, Poteat T, Wirtz AL, Decker MR, et al. Burden of HIV among female
439 sex workers in low-income and middle-income countries: a systematic review and meta-analysis. *Lancet*
440 *Infect Dis*. 2012;12(7):538-49.
- 441 11. Comins CA, Schwartz SR, Phetlhu DR, Guddera V, Young K, Farley JE, et al. Siyaphambili protocol:
442 An evaluation of randomized, nurse-led adaptive HIV treatment interventions for cisgender female sex
443 workers living with HIV in Durban, South Africa. *Res Nurs Health*. 2019;42(2):107-18.
- 444 12. Comins CA, Schwartz SR, Young K, Mishra S, Guddera V, Mclngana M, et al. Contextualising the
445 lived experience of sex workers living with HIV in South Africa: a call for a human-centred response to
446 sexual and reproductive health and rights. *Sex Reprod Health Matters*. 2019;27(1):1686200.
- 447 13. Schwartz S, Lambert A, Phaswana-Mafuya N, Kose Z, Mclngana M, Holland C, et al. Engagement
448 in the HIV care cascade and barriers to antiretroviral therapy uptake among female sex workers in Port
449 Elizabeth, South Africa: findings from a respondent-driven sampling study. *Sex Transm Infect*.
450 2017;93(4):290-6.
- 451 14. Beattie TS, Smilenova B, Krishnaratne S, Mazzuca A. Mental health problems among female sex
452 workers in low- and middle-income countries: A systematic review and meta-analysis. *PLoS Med*.
453 2020;17(9):e1003297.
- 454 15. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. *Br Med*
455 *Bull*. 2010;96:5-21.
- 456 16. EuroQol Research Foundation. EQ-5D-3L User Guide. Basic information on how to use the EQ-
457 5D-3L instrument. Version 6.0. 2018 December.
- 458 17. Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-Related Quality of Life in Patients With
459 Different Diseases Measured With the EQ-5D-5L: A Systematic Review. *Front Public Health*.
460 2021;9:675523.
- 461 18. Tran BX, Ohinmaa A, Nguyen LT. Quality of life profile and psychometric properties of the EQ-
462 5D-5L in HIV/AIDS patients. *Health Qual Life Outcomes*. 2012;10:132.
- 463 19. Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a
464 systematic review of the literature. *Qual Life Res*. 2021;30(3):647-73.

- 465 20. Rinaldi G, Kiadaliri AA, Haghparast-Bidgoli H. Cost effectiveness of HIV and sexual reproductive
466 health interventions targeting sex workers: a systematic review. *Cost Eff Resour Alloc.* 2018;16:63.
- 467 21. Jelsma J, Hansen K, De Weerd W, De Cock P, Kind P. How do Zimbabweans value health states?
468 *Popul Health Metr.* 2003;1(1):11.
- 469 22. Dolan P. Modeling valuations for EuroQol health states. *Med Care.* 1997;35(11):1095-108.
- 470 23. National Institute for Health and Clinical Excellence. Guide to the methods of technology
471 appraisal 2013. London; 2013 April 4.
- 472 24. Thomas R, Burger R, Harper A, Kanema S, Mwenge L, Vanqa N, et al. Differences in health-
473 related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-
474 sectional baseline survey of the HPTN 071 (PopART) trial. *Lancet Glob Health.* 2017;5(11):e1133-e41.
- 475 25. Cribari-Neto F, Zeileis, A., . Beta regression in R. 2009.
- 476 26. Thomas J. Leeper. Interpreting Regression Results using Average Marginal Effects with R's
477 margins 2021 January 21.
- 478 27. World Bank. Data country profile: South Africa [Available from:
479 [https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=CountryProfile&Id=b4](https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=ZAF)
480 [50fd57&tbar=y&dd=y&inf=n&zm=n&country=ZAF](https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=ZAF).
- 481 28. Morton F, Nijjar J. eq5d: Methods for Analysing 'EQ-5D' Data and Calculating 'EQ-5D' Index
482 Scores. CRAN Repository; 2021.
- 483 29. Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature
484 review of the syndemic. *J Womens Health (Larchmt).* 2011;20(7):991-1006.
- 485 30. Allen C, Murphy A, Kiselbach S, VandenBerg S, Wiebe E. Exploring the experience of chronic pain
486 among female Survival Sex Workers: a qualitative study. *BMC Fam Pract.* 2015;16:182.
- 487 31. Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis.
488 *Clin Neuropharmacol.* 2012;35(5):235-43.
- 489 32. Gilbert L, Raj A, Hien D, Stockman J, Terlikbayeva A, Wyatt G. Targeting the SAVA (Substance
490 Abuse, Violence, and AIDS) Syndemic Among Women and Girls: A Global Review of Epidemiology and
491 Integrated Interventions. *J Acquir Immune Defic Syndr.* 2015;69 Suppl 2:S118-27.
- 492 33. World Health Organization. WHOQoL-HIV Bref. World Health Organization. In: dependence
493 Mheardomhas, editor. Geneva2002.
- 494 34. Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of
495 health-related quality-of-life measures for use in HIV/AIDS clinical trials. *Pharmacoeconomics.*
496 2006;24(8):751-65.
- 497 35. Boring BL, Walsh KT, Nanavaty N, Ng BW, Mathur VA. How and Why Patient Concerns Influence
498 Pain Reporting: A Qualitative Analysis of Personal Accounts and Perceptions of Others' Use of Numerical
499 Pain Scales. *Frontiers in Psychology.* 2021;12:2232.
- 500 36. Haghghat R. The Development of an Instrument to Measure Stigmatization: factor analysis and
501 origin of stigmatization. *The European journal of psychiatry.* 2005;19(3):144-54.
- 502 37. Grosso AL, Ketende SC, Stahlman S, Ky-Zerbo O, Ouedraogo HG, Kouanda S, et al. Development
503 and reliability of metrics to characterize types and sources of stigma among men who have sex with men
504 and female sex workers in Togo and Burkina Faso. *BMC Infect Dis.* 2019;19(1):208.
- 505 38. Andersson GZ, Reinius M, Eriksson LE, Svedhem V, Esfahani FM, Deuba K, et al. Stigma reduction
506 interventions in people living with HIV to improve health-related quality of life. *Lancet HIV.*
507 2020;7(2):e129-e40.
- 508 39. Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. *HIV*
509 *AIDS (Auckl).* 2012;4:117-24.
- 510 40. Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, et al. Everything fine so
511 far? Physical and mental health in HIV-infected patients with virological success and long-term exposure
512 to antiretroviral therapy. *J Int AIDS Soc.* 2014;17(4 Suppl 3):19673.

513 **Table 1.** Characteristics of female sex workers living with HIV in Durban, South Africa, 2018-2020.

Characteristics	Total (N=1363)
Age in years	
18-24	228 (16.7%)
25-34	707 (51.9%)
35-44	314 (23.0%)
45-65	114 (8.4%)
Self-identified as Black	1327 (97.4%)
Completed secondary school or higher	263 (19.3%)
ART experience*	
ART naive	178 (13.1%)
Currently off ART	303 (22.2%)
Currently on ART	880 (64.6%)
CD4 count, cells/mm ³ *	
≥500	658 (48.3%)
350-499	257 (18.9%)
200-349	207 (15.2%)
<200	162 (11.9%)
Viral load, copies/ml*	
<50	510 (37.4%)
50-1000	206 (15.1%)
>1000	642 (47.1%)
Drug use**, past 30 days	853 (62.6%)
Injection drug use, ever*	54 (4.0%)
Homelessness, past 6 months*	397 (29.1%)
Experience of physical or sexual violence, ever*	835 (61.3%)
Experience with stigma, ever***	
No	406 (29.8%)
Slight	388 (28.5%)
Moderate	306 (22.5%)
Extreme	263 (19.3%)
Internalized stigma****	
No	544 (39.9%)
Slight	282 (20.7%)
Moderate	313 (23.0%)
Extreme	224 (16.4%)

514 *2, 79, 5, 5, 2, and 1 Individuals have missing information on ART experience, CD4 count, viral load, injection drug use,
515 homelessness, and violence experience, respectively;

516 **Use of any of the following drugs: marijuana, cocaine, woonga/nyaope/sugar, ecstasy, tik/meth, heroin, crack/rock, and flakk;

517 ***HIV or sex work related stigma, ever; details on stigma measures in **Appendix A1**; ****sex work related; details on stigma
518 measures in **Appendix A1**;

519 Abbreviations: ART, antiretroviral treatment

520 **Table 2.** EQ-5D health-related quality of life (HRQoL) score* and visual analogue scale (EQ-VAS) among
521 female sex workers living with HIV in Durban, South Africa, 2018-2020.

Characteristics	EQ-5D HRQoL score			EQ-VAS		
	Mean (SD)	Median (IQR)	P-value*	Mean (SD)	Median (IQR)	P-value*
Total	0.857 (0.187)	1.00 [0.787, 1.00]		57.7 (21.9)	52.0 [50.0, 70.0]	
Age in years			0.004			0.18
18-24	0.891 (0.157)	1.00 [0.787, 1.00]		57.5 (21.1)	53.0 [50.0, 70.0]	
25-34	0.859 (0.189)	1.00 [0.787, 1.00]		57.2 (22.2)	52.0 [50.0, 70.0]	
35-44	0.846 (0.191)	0.854 [0.787, 1.00]		57.5 (21.5)	52.0 [50.0, 70.0]	
45-65	0.811 (0.210)	0.854 [0.727, 1.00]		62.1 (21.8)	58.0 [50.0, 80.0]	
Self-identified as black race			0.008			0.97
Yes	0.859 (0.186)	1.00 [0.787, 1.00]		57.8 (21.7)	52.0 [50.0, 70.0]	
No	0.776 (0.207)	0.854 [0.660, 1.00]		56.3 (25.8)	55.5 [47.5, 74.3]	
Completed secondary school or higher			0.31			0.42
Yes	0.866 (0.184)	1.00 [0.787, 1.00]		58.8 (24.7)	54.0 [47.0, 75.5]	
No	0.855 (0.188)	1.00 [0.787, 1.00]		57.5 (21.1)	52.0 [50.0, 70.0]	
ART experience			0.004			<0.001
ART naive	0.842 (0.195)	0.854 [0.787, 1.00]		54.2 (20.5)	51.0 [45.0, 62.0]	
Currently off ART	0.827 (0.206)	0.854 [0.727, 1.00]		49.1 (21.7)	50.0 [40.0, 60.0]	
Currently on ART	0.870 (0.177)	1.00 [0.787, 1.00]		61.4 (21.2)	56.0 [50.0, 75.0]	
CD4, cells/mm ³			0.76			<0.001
≥500	0.855 (0.183)	1.00 [0.787, 1.00]		59.4 (22.8)	54.0 [50.0, 75.0]	
350-499	0.860 (0.196)	1.00 [0.787, 1.00]		57.6 (21.0)	52.0 [50.0, 70.0]	
200-349	0.865 (0.175)	1.00 [0.787, 1.00]		53.6 (20.0)	50.0 [45.0, 62.0]	
<200	0.846 (0.204)	1.00 [0.787, 1.00]		55.7 (20.6)	52.0 [47.8, 70.0]	
Viral load, copies/ml			0.62			<0.001
<50	0.860 (0.180)	1.00 [0.787, 1.00]		61.6 (21.7)	56.0 [50.0, 75.8]	
50-1000	0.847 (0.192)	1.00 [0.744, 1.00]		57.4 (21.8)	51.0 [50.0, 70.0]	
>1000	0.859 (0.191)	1.00 [0.787, 1.00]		54.8 (21.6)	51.0 [45.0, 67.0]	
Drug use, past 30 days			<0.001			<0.001
Yes	0.844 (0.191)	0.854 [0.787, 1.00]		55.8 (21.7)	51.0 [47.0, 70.0]	
No	0.879 (0.178)	1.00 [0.787, 1.00]		61.0 (21.8)	56.0 [50.0, 75.0]	
Injection drug use, ever			0.95			0.082
Yes	0.861 (0.177)	1.00 [0.787, 1.00]		54.1 (17.6)	50.0 [45.0, 63.5]	
No	0.857 (0.187)	1.00 [0.787, 1.00]		57.8 (22.0)	52.0 [50.0, 70.0]	
Homelessness, past 6 months			0.014			<0.001
Yes	0.840 (0.194)	0.854 [0.777, 1.00]		54.5 (21.4)	51.0 [45.0, 65.0]	
No	0.864 (0.184)	1.00 [0.787, 1.00]		59.1 (21.9)	54.0 [50.0, 72.0]	
Experience of physical or sexual violence, ever			<0.001			<0.001

Yes	0.837 (0.197)	0.854 [0.777, 1.00]	55.0 (21.4)	51.0 [47.0, 67.0]	
No	0.888 (0.165)	1.00 [0.787, 1.00]	62.0 (21.9)	56.0 [50.0, 80.0]	
Experience with stigma ***			0.33		<0.00 1
No	0.858 (0.188)	1.00 [0.787, 1.00]	62.0 (22.5)	57.5 [50.0, 80.0]	
Slight	0.861 (0.189)	1.00 [0.787, 1.00]	60.0 (19.7)	53.5 [50.0, 71.0]	
Moderate	0.863 (0.184)	1.00 [0.787, 1.00]	54.5 (21.3)	51.0 [46.3, 69.0]	
Extreme	0.844 (0.186)	0.854 [0.787, 1.00]	51.4 (22.5)	50.0 [40.5, 61.5]	
Internalized stigma****			0.07		<0.00 1
No	0.868 (0.178)	1.00 [0.787, 1.00]	60.0 (21.2)	54.0 [50.0, 71.0]	
Slight	0.858 (0.186)	1.00 [0.787, 1.00]	60.2 (21.2)	55.0 [50.0, 73.8]	
Moderate	0.830 (0.204)	0.854 [0.787, 1.00]	56.9 (22.2)	52.0 [43.0, 70.0]	
Extreme	0.867 (0.182)	1.00 [0.787, 1.00]	50.3 (22.2)	50.0 [41.0, 60.0]	


522 *HRQoL score was calculated using the Zimbabwe general population value set; **Wilcoxon rank sum tests, and Kruskal-Wallis
523 tests were used to compare median values in the HRQoL score and EQ-VAS by binary variables and by other categorical variables,
524 respectively; ***HIV or sex work related stigma, ever; details on stigma measures in **Appendix A1**; ****sex work related; details on
525 stigma measures in **Appendix A1**;
526 Abbreviations: EQ-5D, EuroQoL five dimension; SD, standard deviation; IQR, inter quartile range; ART, antiretroviral treatment.
527

528 **Table 3.** Multivariable analyses of factors associated with the EQ-5D health-related quality of life
 529 (HRQoL) score and the visual analogue scale (EQ-VAS) of female sex workers living with HIV in Durban,
 530 South Africa, 2018-2020.

Characteristics	Point	Average marginal change in EQ-5D HRQoL score*			P-value	Average marginal change in EQ-VAS**		
		Lower	Upper	Point		Lower	Upper	
Age in years (per ten-year increase)	-0.018	-0.027	-0.008	<0.001	0.005	-0.020	0.011	
Completed secondary school or higher (yes vs no)	0.006	-0.011	0.022	0.49	0.014	-0.015	0.043	
Current on ART (yes vs no)	0.015	-0.001	0.031	0.062	0.080	0.054	0.106	
CD4<200, cells/mm ³ (yes vs no)	-0.002	-0.023	0.019	0.85	-0.011	-0.046	0.024	
Viral suppression (<50 copies/ml) (yes vs no)	-0.008	-0.024	0.008	0.32	0.021	-0.005	0.048	
Drug use, past 30 days (yes vs no)	-0.022	-0.036	-0.007	0.003	-0.018	-0.043	0.007	
Homelessness, past 6 months (yes vs no)	-0.008	-0.024	0.007	0.29	-0.027	-0.053	-0.001	
Experience of physical or sexual violence, ever (yes vs no)	-0.024	-0.038	-0.010	<0.001	-0.036	-0.060	-0.012	
Experience with stigma (slight vs no)***	0.005	-0.013	0.022	0.61	-0.012	-0.042	0.018	
Experience with stigma (moderate vs no)***	0.011	-0.008	0.029	0.25	-0.059	-0.092	-0.027	
Experience with stigma (extreme vs no)***	-0.002	-0.023	0.019	0.86	-0.078	-0.112	-0.043	
Internalized stigma (slight vs no)****	-0.008	-0.026	0.010	0.37	0.000	-0.031	0.031	
Internalized stigma (moderate vs no) ****	-0.023	-0.041	-0.004	0.016	-0.042	-0.072	-0.012	
Internalized stigma (extreme vs no) ****	0.0003	-0.018	0.019	0.98	-0.085	-0.119	-0.052	


531 Estimated using beta regression with complementary loglog link; the HRQoL score was calculated using the Zimbabwe general
 532 population value set; *Estimated using linear regression; EQ-VAS scaled to 0-1 from 0-100; ***HIV or sex work related stigma, ever;
 533 details on stigma measures in **Appendix A1**; ****sex work related; details on stigma measures in **Appendix A1**; Abbreviations: EQ-
 534 5D, EuroQoL five dimension; ART, antiretroviral treatment.
 535

536 **Figures:**
537



538 **Figure 1.** Health-related quality of life profile of female sex workers living with HIV in Durban, South
539 Africa, 2018-2020. (A) Proportion of women reporting problems on each EQ-5D-3L domain. (B) Most
540 frequent EQ-5D-3L health states. For example, health state 11123 refers to no problems in mobility, self-
541 care and usual activity, moderate problems in pain/discomfort, and extreme problems in
542 anxiety/depression. *Numbers in the bracket denote the cumulative percentage of health states from top
543 to bottom. (C) Distribution of EQ-5D-3L preference-weighted summary index (HRQoL score, representing
544 health utility), in which 1 denotes no problems in any of the five domains and 0 denotes a health state
545 equivalent to death. (D) Distribution of EQ-5D visual analogue scale, in which participants are asked to
546 rate their quality of life on a “thermometer” from 0 (equivalent to death) to 100 (perfect health).
547 Abbreviations: EQ-5D-3L, EuroQoL five dimensions, three levels; HRQoL, health-related quality of life.
548
549

550



551

552

553 **Figure 2.** Estimated mean and 95% confidence intervals of health-related quality of life (HRQoL) score
 554 (representing health utility) for subgroups of female sex workers (FSW) living with HIV in Durban, South
 555 Africa by current antiretroviral treatment (ART) use. Values estimated using the fitted multivariable beta
 556 regression model, setting the rest of covariates (age, education, CD4 count, viral suppression,
 557 homelessness, experience with stigma and internalized stigma) at the sample average values.

558